Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington’s
Our CEO David Reynolds spoke with Amy Brown from BiotechTV on LoQus23’s unique approach to Huntington’s disease, investigating small molecule drugs that could stop DNA instability and slow neurodegeneration.
